HAEM5:Acute monocytic leukaemia: Difference between revisions

[checked revision][checked revision]
No edit summary
No edit summary
Line 82: Line 82:




<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote>


*Common manifestations include extramedullary masses, lymphadenopathy, cutaneous and gingival infiltration, CNS involvement and presenting with bleeding disorders<ref name=":0" />
*Common manifestations include extramedullary masses, lymphadenopathy, cutaneous and gingival infiltration, CNS involvement and presenting with bleeding disorders<ref name=":0" />
*May present with acute respiratory failure<ref>{{Cite journal|last=Azoulay|first=Elie|last2=Fieux|first2=Fabienne|last3=Moreau|first3=Delphine|last4=Thiery|first4=Guillaume|last5=Rousselot|first5=Philippe|last6=Parrot|first6=Antoine|last7=Le Gall|first7=Jean-Roger|last8=Dombret|first8=Hervé|last9=Schlemmer|first9=Benoît|date=2003|title=Acute monocytic leukemia presenting as acute respiratory failure|url=https://www.ncbi.nlm.nih.gov/pubmed/12574074|journal=American Journal of Respiratory and Critical Care Medicine|volume=167|issue=10|pages=1329–1333|doi=10.1164/rccm.200206-554OC|issn=1073-449X|pmid=12574074}}</ref>
*May present with acute respiratory failure<ref>{{Cite journal|last=Azoulay|first=Elie|last2=Fieux|first2=Fabienne|last3=Moreau|first3=Delphine|last4=Thiery|first4=Guillaume|last5=Rousselot|first5=Philippe|last6=Parrot|first6=Antoine|last7=Le Gall|first7=Jean-Roger|last8=Dombret|first8=Hervé|last9=Schlemmer|first9=Benoît|date=2003|title=Acute monocytic leukemia presenting as acute respiratory failure|url=https://www.ncbi.nlm.nih.gov/pubmed/12574074|journal=American Journal of Respiratory and Critical Care Medicine|volume=167|issue=10|pages=1329–1333|doi=10.1164/rccm.200206-554OC|issn=1073-449X|pmid=12574074}}</ref>


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
==Sites of Involvement==
==Sites of Involvement==
Line 150: Line 153:


<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 161: Line 164:
|}
|}


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>


Line 168: Line 174:
* Individual Region Genomic Gain/Loss/LOH
* Individual Region Genomic Gain/Loss/LOH
* Characteristic Chromosomal Patterns
* Characteristic Chromosomal Patterns
* Gene Mutations (SNV/INDEL)}}
* Gene Mutations (SNV/INDEL)}}</blockquote>


Diagnosis
Diagnosis
Line 180: Line 186:
*Multiple studies have shown that t(8;16)(p11.2;p13.3) positive AML usually has a poor prognosis<ref>{{Cite journal|last=Heim|first=S.|last2=Avanzi|first2=G. C.|last3=Billström|first3=R.|last4=Kristoffersson|first4=U.|last5=Mandahl|first5=N.|last6=Bekassy|first6=A. N.|last7=Garwicz|first7=S.|last8=Wiebe|first8=T.|last9=Pegoraro|first9=L.|date=1987|title=A new specific chromosomal rearrangement, t(8;16) (p11;p13), in acute monocytic leukaemia|url=https://www.ncbi.nlm.nih.gov/pubmed/3476150|journal=British Journal of Haematology|volume=66|issue=3|pages=323–326|doi=10.1111/j.1365-2141.1987.tb06917.x|issn=0007-1048|pmid=3476150}}</ref><ref>{{Cite journal|last=Haferlach|first=T.|last2=Kohlmann|first2=A.|last3=Klein|first3=H.-U.|last4=Ruckert|first4=C.|last5=Dugas|first5=M.|last6=Williams|first6=P. M.|last7=Kern|first7=W.|last8=Schnittger|first8=S.|last9=Bacher|first9=U.|date=2009|title=AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features|url=https://www.ncbi.nlm.nih.gov/pubmed/19194466|journal=Leukemia|volume=23|issue=5|pages=934–943|doi=10.1038/leu.2008.388|issn=1476-5551|pmid=19194466}}</ref>.
*Multiple studies have shown that t(8;16)(p11.2;p13.3) positive AML usually has a poor prognosis<ref>{{Cite journal|last=Heim|first=S.|last2=Avanzi|first2=G. C.|last3=Billström|first3=R.|last4=Kristoffersson|first4=U.|last5=Mandahl|first5=N.|last6=Bekassy|first6=A. N.|last7=Garwicz|first7=S.|last8=Wiebe|first8=T.|last9=Pegoraro|first9=L.|date=1987|title=A new specific chromosomal rearrangement, t(8;16) (p11;p13), in acute monocytic leukaemia|url=https://www.ncbi.nlm.nih.gov/pubmed/3476150|journal=British Journal of Haematology|volume=66|issue=3|pages=323–326|doi=10.1111/j.1365-2141.1987.tb06917.x|issn=0007-1048|pmid=3476150}}</ref><ref>{{Cite journal|last=Haferlach|first=T.|last2=Kohlmann|first2=A.|last3=Klein|first3=H.-U.|last4=Ruckert|first4=C.|last5=Dugas|first5=M.|last6=Williams|first6=P. M.|last7=Kern|first7=W.|last8=Schnittger|first8=S.|last9=Bacher|first9=U.|date=2009|title=AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features|url=https://www.ncbi.nlm.nih.gov/pubmed/19194466|journal=Leukemia|volume=23|issue=5|pages=934–943|doi=10.1038/leu.2008.388|issn=1476-5551|pmid=19194466}}</ref>.


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
==Individual Region Genomic Gain / Loss / LOH==
==Individual Region Genomic Gain / Loss / LOH==
Line 250: Line 259:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>


Myeloid-associated nonspecific cytogenetic abnormalities are present in most cases.
Myeloid-associated nonspecific cytogenetic abnormalities are present in most cases.


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
==Gene Mutations (SNV / INDEL)==
==Gene Mutations (SNV / INDEL)==